Arthrogryposis market seen growing 5.2% annually to 2030

The global arthrogryposis market is projected to rise from $1.04 billion in 2026 to $1.27 billion by 2030, according to The Business Research Company. Growth is being driven by rising congenital disorder diagnoses, telehealth adoption and expanding demand for early screening and long-term rehabilitation.

Why it matters: - Arthrogryposis care affects patients with congenital joint contractures that can limit mobility and require long-term treatment. - Market growth signals expanding demand for pediatric orthopedic care, rehabilitation services and advanced diagnostics. - The forecast points to greater investment in rare disease research and supportive care for patients and families.

What happened: - The Business Research Company released its Arthrogryposis Market Global Market Report 2026. - The report projects the market will grow from $1.04 billion in 2026 to $1.27 billion by 2030. - The forecast implies a 5.2% compound annual growth rate over the period. - The report says the market increased from $0.98 billion in 2025 to $1.04 billion in 2026, a 5.5% CAGR in the historical period. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Arthrogryposis includes congenital conditions marked by multiple joint contractures, stiffness and limited mobility. - The condition is linked to decreased fetal movement during pregnancy. - Neurological, muscular or connective tissue abnormalities can contribute to the disorder. - Historical growth has been supported by better clinical knowledge of congenital disorders, more pediatric orthopedic services, wider rehabilitation access, greater use of physical therapy and more specialized treatment centers. - Future growth drivers include rising investment in rare disease research, demand for personalized rehabilitation programs, broader early screening, stronger focus on long-term quality of life and more advanced diagnostic technologies. - Key market trends include earlier diagnosis, multidisciplinary treatment strategies, more sophisticated imaging, expanded long-term rehabilitation and improved supportive care. - Rising incidence of congenital disorders worldwide is a major market driver. - The World Health Organization said in February 2023 that nearly 240,000 newborns globally die from congenital disorders within their first 28 days. - The World Health Organization also estimated 170,000 child deaths between ages 1 month and 5 years from congenital disorders. - Telehealth is expanding access to early diagnosis, ongoing management and specialist consultations for arthrogryposis patients. - Australian Digital Health Agency data from May 2024 showed more than 95,000 practitioners had used telehealth platforms. - The same data showed 118.2 million telehealth services delivered to about 18 million patients over two years. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables. - The company is offering a free sample and the full report through its website: Free sample report and the full market report.

Between the lines: - The market outlook suggests rare disease categories are gaining more commercial attention as screening and diagnostics improve. - Telehealth adoption may matter disproportionately for arthrogryposis because mobility challenges make remote care more practical. - The regional split suggests mature healthcare systems are still dominant, but new patient identification and spending growth may be shifting toward Asia-Pacific.

What's next: - The report expects early screening, advanced diagnostics and rehabilitation services to remain the main growth engines through 2030. - Market participants will likely focus on multidisciplinary care models and longer-term support programs as treatment expectations rise. - The Business Research Company says its 2026 reports also include updated graphics, tables and forecasting tools.